PE20240138A1 - Formas cristalinas de un compuesto farmaceutico - Google Patents

Formas cristalinas de un compuesto farmaceutico

Info

Publication number
PE20240138A1
PE20240138A1 PE2023001212A PE2023001212A PE20240138A1 PE 20240138 A1 PE20240138 A1 PE 20240138A1 PE 2023001212 A PE2023001212 A PE 2023001212A PE 2023001212 A PE2023001212 A PE 2023001212A PE 20240138 A1 PE20240138 A1 PE 20240138A1
Authority
PE
Peru
Prior art keywords
crystalline forms
pharmaceutical compound
crystalline form
crystalline
compound
Prior art date
Application number
PE2023001212A
Other languages
English (en)
Spanish (es)
Inventor
Robert Hett
Fritz Blatter
Jennifer Robin
Kyle Landskroner
Original Assignee
Azafaros B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azafaros B V filed Critical Azafaros B V
Publication of PE20240138A1 publication Critical patent/PE20240138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2023001212A 2020-10-02 2021-10-01 Formas cristalinas de un compuesto farmaceutico PE20240138A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound

Publications (1)

Publication Number Publication Date
PE20240138A1 true PE20240138A1 (es) 2024-01-30

Family

ID=72744696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001212A PE20240138A1 (es) 2020-10-02 2021-10-01 Formas cristalinas de un compuesto farmaceutico

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC7.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240056628A (cg-RX-API-DMAC7.html)
CN (1) CN116390910A (cg-RX-API-DMAC7.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3193939C (cg-RX-API-DMAC7.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC7.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC7.html)
IL (2) IL316634A (cg-RX-API-DMAC7.html)
MA (1) MA58885B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003618A (cg-RX-API-DMAC7.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC7.html)
TW (1) TWI912383B (cg-RX-API-DMAC7.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Also Published As

Publication number Publication date
WO2022069709A1 (en) 2022-04-07
JP7809655B2 (ja) 2026-02-02
AU2021353055B2 (en) 2022-10-06
TWI912383B (zh) 2026-01-21
TW202229236A (zh) 2022-08-01
EP3978474A1 (en) 2022-04-06
MX2023003618A (es) 2023-07-14
AU2022291486A1 (en) 2023-02-02
ES2964105T3 (es) 2024-04-04
FI4114826T3 (fi) 2023-11-21
IL301882B1 (en) 2024-12-01
EP4114826A1 (en) 2023-01-11
CL2023000943A1 (es) 2023-09-29
DK4114826T3 (da) 2023-11-13
NZ798892A (en) 2023-09-29
IL301882A (en) 2023-06-01
CN116390910A (zh) 2023-07-04
KR20240056628A (ko) 2024-04-30
BR112022018020A2 (pt) 2023-04-18
JP2024054192A (ja) 2024-04-16
IL301882B2 (en) 2025-04-01
BR112022018020B1 (pt) 2023-12-26
CA3193939C (en) 2024-02-20
EP4295847A3 (en) 2024-02-28
US20230391724A1 (en) 2023-12-07
ZA202310184B (en) 2024-01-31
AU2021353055A1 (en) 2022-09-15
KR20230078798A (ko) 2023-06-02
US12116344B2 (en) 2024-10-15
AU2022291486B2 (en) 2024-07-25
US20250059137A1 (en) 2025-02-20
KR102659466B1 (ko) 2024-04-19
US20240287001A9 (en) 2024-08-29
JP2023524169A (ja) 2023-06-08
CA3193939A1 (en) 2022-04-07
IL316634A (en) 2024-12-01
EP4295847A2 (en) 2023-12-27
MA58885B1 (fr) 2023-11-30
EP4114826B1 (en) 2023-08-23
BR122022018214A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CO2017007679A2 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
PH12020500446A1 (en) Bisamide sarcomere activating compounds and uses thereof
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
MX2019003373A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
DOP2016000161A (es) Ureas asimétricas p- sustituidas y usos médicos de las mismas.
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX378012B (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2018007432A (es) Compuestos de dihidroquinolinsulfonamida de alquilo.